

# Corporate Action Notice



May 1, 2019

## Ratio Change and Reverse Stock Split

### Can-Fite Biopharma

**DR CUSIP:** 13471N102 / **DR ISIN:** US13471N102

**DR Ticker Symbol:** CANF

**Ratio (DS: Underlying Shares):** 1: 2

The Bank of New York Mellon, at the direction of Can-Fite Biopharma is announcing a ratio change on the Depositary Receipt ("DR") program from one (1) Depositary Share ("DS") representing two (2) Ordinary shares to a new ratio of one (1) DS representing thirty (30) Ordinary shares.

The ratio change will result in a reverse split on the Can-Fite Biopharma DSs on the basis of one (1) new DS for every fifteen (15) old DSs held. The ordinary shares of Can-Fite Biopharma will not be affected by this change in the DS to ordinary share ratio.

Effective May 10, 2019, DS holders of Can-Fite Biopharma will be required on a mandatory basis to surrender their old DSs to BNY Mellon for cancellation and exchange at the rate of fifteen (15) "Old" DSs (CUSIP 13471N102) for one (1) "New" DS (13471N201). Holders in the Direct Registration System or in brokerage accounts will have their DSs automatically exchanged and need not take any action. Only whole DSs will be distributed. BNY Mellon will attempt to sell any fractional DSs and distribute the cash proceeds.

### Please note below the timetable for the reverse stock split:

Effective date:	May 10, 2019
Exchange Ratio:	1 "New" DS for every 15 "Old" DSs
Old CUSIP:	13471N102
Old Ratio:	1 DS: 2 Ordinary share
New CUSIP:	13471N201
New Ratio:	1 DS: 30 Ordinary shares
Cancellation Fee:	\$0.000000

### Please note: A ratio change may impact the fees payable by DR investors.

BNY Mellon's books will be closed for all issuance and cancellation transactions on CUSIP 13471N102 from the close of business May 9, 2019. BNY Mellon anticipates that on May 10, 2019, the books will be opened for all issuance and cancellation transactions on CUSIP 13471N201.

To learn more about DRs, please contact [DRBrokerSolutions@bnymellon.com](mailto:DRBrokerSolutions@bnymellon.com) or visit our website at [adrbnymellon.com](http://adrbnymellon.com).

**PLEASE SEE INVESTOR DISCLOSURE ON LAST PAGE.**

## Investor Disclosure

This notice and the information and data provided herein are provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data. BNY Mellon does not undertake any obligation to update or amend this notice or any information or data, and may change, update or amend this notice or any information or data at any time without prior notice.

BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such. We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon this notice or any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

BNY Mellon collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued. From time to time, BNY Mellon may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates; in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at [https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset\\_upload\\_file49220\\_197380.pdf](https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset_upload_file49220_197380.pdf).

This notice or any excerpt of this notice may not be copied or reproduced without the prior express written consent of BNY Mellon.

BNY Mellon is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle. BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BK).

BNY Mellon's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY Mellon.

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY MELLON AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.